Generation Bio Co
(NAS:GBIO)
$
2.32
0.01 (0.43%)
Market Cap: 154.84 Mil
Enterprise Value: 31.19 Mil
PE Ratio: 0
PB Ratio: 1.34
GF Score: 32/100 Generation Bio Co on Investigative Non-Viral Gene Therapy Transcript
Mar 05, 2021 / NTS GMT
Release Date Price:
$32.75
(-5.43%)
Amy Board
BloodStream Media - Moderator
This week on BloodStream, we get a preview to the March episode of flow with hematologist and founder of Let's Talk Period, Dr. Paula James with my guest host, Jessica Richmond. And, hey, what's all this discussion about nonviral gene therapy? We'll hear from Doug Kerr, Chief Medical Officer from Generation Bio to tell us all about it.
Doug Kerr
Generation Bio Co. - Chief Medical Officer
AAV gene therapy is a one stop therapy. You've got one shot at. And one of the advantages of nonviral gene therapy is we can re-dose as often as we need to get every patient into the right range.
Amy Board
BloodStream Media - Moderator
Hi, all. I'm your host, Amy board. And today I have a guest host.
Jessica Richmond
BloodStream Media - Moderator
It's me, Jessica Richmond. Hi.
Amy Board;Jessica Richmond
BloodStream Media - Moderator;
Reminder, Jess and I are podcasters.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot